Abstract: The present invention relates to nutrition for dysphagia. More specifically it relates to a thickened composition for use in decreasing the laryngeal vestibule closure (LVC) time and/or decreasing the duration of swallowing response in a dysphagia patient, wherein the thickened composition comprises a thickening agent comprising galactomannan polysaccharide. The invention also pertains to a thickening agent for use in decreasing the laryngeal vestibule closure (LVC) time and/or decreasing the duration of swallowing response in a dysphagia patient who is consuming a composition to which the thickening agent comprising galactomannan polysaccharide has been added.

Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a food composition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.

Abstract: The present invention relates to a liquid nutritional composition, to a liquid nutritional composition for use in a diagnostic method for screening of a glucose-intolerant condition, to a kit for screening of a glucose-intolerant condition, and to a diagnostic method for screening a mammal for a glucose-intolerant condition. Furthermore, it refers to a liquid nutritional composition for use as a standard reference nutrition, such as for classification of postprandial glucose responses of different nutritional compositions. The liquid nutritional composition comprises protein, fat, digestible carbohydrate and dietary fibre, wherein the digestible carbohydrate comprises at least 90 weight % of glucose units, based on total digestible carbohydrate mass and preferably is substantially free of fructose.

Abstract: The present invention is directed at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of inflammation or infection, wherein the combination is to be administered enterally and at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of an imbalance in the metabolic use of amino acid resources from the body or from nutrition in a subject having an inflammation or an infection, wherein the combination is to be administered enterally.

Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a foodcomposition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.

Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a food composition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.

Abstract: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.

Abstract: The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and/or phytostanols capable of reducing cholesterol absorption in the intestine and/or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants.

Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a foodcomposition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.

Abstract: One aspect of the present invention relates to a method of preventing multiple organ dysfunction syndrome in a mammal suffering from trauma, said method comprising enterally administering to said mammal, within 24 hours of the occurrence of the trauma, (i) digestible water soluble carbohydrates and (ii) a liver guanosine-5?-triphosphate (GTP) increasing component and/or peptides with Angiotensin Converting Enzyme (ACE) inhibiting activity. Another aspect of the invention relates to an aqueous liquid composition containing: ?20-200 g/l digestible dissolved carbohydrates; ?5-5000 mg/l guanosine equivalents in combination with 1-100 g/l ribose equivalents and/or 2-2000 mg/l flavonoides; or 0.01 to 10 mM of peptides with ACE inhibiting activity; and ?45 to 97.95 wt. % water.

Abstract: The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as suitable composition comprising (a) one or more phytosterols and/orphytostanols or a mixture thereof capable of reducing cholesterol absorption in the intestine, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions b. and c. is preferably derived from plants.

Abstract: The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and/or phytostanols capable of reducing cholesterol absorption in the intestine and/or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants.

Abstract: The present invention relates to the use of one or more of apigenin, luteolin and morin and functional analogues thereof for the manufacture of a preparation for the treatment and/or prevention of a disorder related to altered bone metabolism, in particular osteoporosis, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodistrophy in liver disease or the altered bone metabolism caused by renal failure or haemodialysis, bone fracture, bone surgery, pregnancy, anorexia nervosa, and in immobile, malnourished and weight losing persons.

Abstract: The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as suitable composition comprising (a) one or more phytosterols and/or phytostanols or a mixture thereof capable of reducing cholesterol absorption in the intestine, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions b. and c. is preferably derived from plants.